Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Apellis Pharmaceuticals Inc shares valued at $737,536 were sold by Dunlop A. Sinclair on Oct 10 ’25. At $23.72 per share, Dunlop A. Sinclair sold 31,092 shares. The insider’s holdings dropped to 3,837 shares worth approximately $96769.14 following the completion of this transaction.
Also, Dunlop A. Sinclair sold 31,092 shares, netting a total of over 702,057 in proceeds. Following the sale of shares at $22.58 each, the insider now holds 33,979 shares.
Before that, Dunlop A. Sinclair had sold 31,092 shares from its account. In a trade valued at $713,561, the Director traded Apellis Pharmaceuticals Inc shares for $22.95 each. Upon closing the transaction, the insider’s holdings decreased to 31,092 shares, worth approximately $1.74 million.
As published in their initiating research note from Wells Fargo on October 15, 2025, Apellis Pharmaceuticals Inc [APLS] has been an Overweight and the price target has been revised to $32. Analysts at Goldman downgraded the stock from ‘”a Neutral”‘ to ‘”a Sell”‘ outlook in a report released in late September. As of May 09, 2025, Raymond James has decreased its “Strong buy” rating to a “an Outperform” for APLS. Earlier on May 09, 2025, BofA Securities downgraded its rating. Their new recommendation was “a Neutral” for APLS stock which previously was a “a Buy”.
Analyzing APLS Stock Performance
On last trading session, Apellis Pharmaceuticals Inc [NASDAQ: APLS] rose 8.94% to $25.22. The stock’s lowest price that day was $23.88, but it reached a high of $25.39 in the same session. During the last five days, there has been a surge of approximately 1.20%. Over the course of the year, Apellis Pharmaceuticals Inc shares have dropped approximately -7.07%.
Is Apellis Pharmaceuticals Inc subject to short interest?
Stocks of Apellis Pharmaceuticals Inc saw a sharp rise in short interest on 2025-09-30 jumping by 0.51 million shares to 21.05 million. Data from Yahoo Finance shows that the short interest on 2025-08-29 was 20.54 million shares. A jump of 2.41% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 9.23 of the overall float, the days-to-cover ratio (short ratio) jumped to 9.23.
Which companies own the most shares of Apellis Pharmaceuticals Inc (APLS)?
In terms of Apellis Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 22 in the next 12 months, down nearly -4.97% from the previous closing price of $23.15. Analysts anticipate Apellis Pharmaceuticals Inc stock to reach 32 by 2025, with the lowest price target being 18. In spite of this, 14 analysts ranked Apellis Pharmaceuticals Inc stock as Buy at the end of 2025. On April 29, 2025, Cantor Fitzgerald assigned a price target of “an Overweight” to the stock and initiated coverage with a $44.